Jørgen Borrebæk

Targeted cancer therapy with a novel low-dose rate α-emitting radioimmunoconjugate

Jostein Dahle, Jørgen Borrebæk, Thora J. Jónasdóttir et al. · Blood · 2007 · 80 citations · Full text

Experimental α-particle radioimmunotherapy of breast cancer using 227Th-labeled p-benzyl-DOTA-trastuzumab

Nasir Abbas, Helèn Heyerdahl, Øyvind S. Bruland et al. · EJNMMI Research · 2011 · 57 citations · Full text

Initial evaluation of 227Th-p-benzyl-DOTA-rituximab for low-dose rate α-particle radioimmunotherapy

Jostein Dahle, Jørgen Borrebæk, Katrine B. Melhus et al. · Nuclear Medicine and Biology · 2006 · 56 citations

Radiation Medicine, Initial Evaluation, Radiation Therapy +5

Assessment of long-term radiotoxicity after treatment with the low-dose-rate alpha-particle-emitting radioimmunoconjugate 227Th-rituximab

Jostein Dahle, Thora J. Jónasdóttir, Helèn Heyerdahl et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2009 · 43 citations

Low-dose-rate Alpha-particle-emitting Radioimmunoconjugate, Radiation Therapy, Radiobiology +11

Treatment of HER2-Expressing Breast Cancer and Ovarian Cancer Cells With Alpha Particle-Emitting 227Th-Trastuzumab

Helèn Heyerdahl, Cecilie Krogh, Jørgen Borrebæk et al. · International Journal of Radiation Oncology*Biology*Physics · 2011 · 41 citations

Breast Oncology, Her2-expressing Breast Cancer, Alpha Particle-emitting +11